Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 161 to 170 of 281 total matches.
An EUA for Baricitinib (Olumiant) for COVID-19
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
was statistically significant.5
DRUG INTERACTIONS — Strong OAT3 inhibitors such
as probenecid can increase ...
The oral Janus kinase (JAK) inhibitor baricitinib
(Olumiant – Lilly) has been granted an FDA Emergency
Use Authorization (EUA) for treatment of confirmed or
suspected COVID-19 in hospitalized patients ≥2 years
old who require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO); the EUA requires that baricitinib be used
in combination with the IV antiviral drug remdesivir
(Veklury). Baricitinib has been available for treatment
of rheumatoid arthritis since 2018. Remdesivir was
recently approved by the FDA for treatment of COVID-19
in...
Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
.
DRUG INTERACTIONS — Budesonide is a substrate
of CYP3A4; coadministration of CYP3A4 inhibitors ...
The FDA has approved Tarpeyo (Calliditas), a delayed-release
capsule formulation of the corticosteroid
budesonide, to reduce proteinuria in adults with
primary immunoglobulin A nephropathy (IgAN; also
called Berger's disease) who are at risk of rapid
disease progression. It is the fi rst drug to be approved
in the US for this indication. Oral formulations
of budesonide have been available for years for
treatment of inflammatory bowel disease.
Pemigatinib (Pemazyre) for Cholangiocarcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
(FGFR2) fusions or other rearrangements.
Pemigatinib is the first drug to be approved ...
The oral kinase inhibitor pemigatinib (Pemazyre –
Incyte) has received accelerated approval from
the FDA for treatment of adults with previously
treated, unresectable, locally advanced or metastatic
cholangiocarcinoma with fibroblast growth factor
receptor 2 (FGFR2) fusions or other rearrangements.
Pemigatinib is the first drug to be approved in the US
for this indication.
Odevixibat (Bylvay) for Progressive Familial Intrahepatic Cholestasis-Associated Pruritus
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
or hepatic decompensation.
DRUG INTERACTIONS — Odevixibat should not be
administered within 4 hours ...
Odevixibat (Bylvay – Albireo), an oral ileal bile acid
transporter (IBAT) inhibitor, has been approved by the
FDA for treatment of pruritus in patients ≥3 months
old with progressive familial intrahepatic cholestasis
(PFIC). It is the first drug to be approved in the US for
this indication.
Tovorafenib (Ojemda) for Pediatric Low-Grade Glioma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
have been reported. Liver
function tests should be monitored before and
during treatment.
DRUG INTERACTIONS ...
Tovorafenib (Ojemda – Day One), a type II RAF kinase
inhibitor, has received accelerated approval from the
FDA for treatment of patients ≥6 months old with
relapsed or refractory pediatric low-grade glioma
harboring a BRAF fusion or rearrangement or a BRAF
V600 mutation. Tovorafenib is the first systemic
treatment to be approved in the US for pediatric
low-grade gliomas with BRAF fusions. Accelerated
approval of tovorafenib was based on response rates
and duration of response.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):e97-8 doi:10.58347/tml.2024.1704f | Show Introduction Hide Introduction
Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
/drugpricing-
policy.
DRUG INTERACTIONS — Icosapent ethyl might
increase the risk of bleeding in patients ...
Icosapent ethyl (Vascepa – Amarin), the ethyl ester
of eicosapentaenoic acid (EPA), has been approved
by the FDA for use as an adjunct to maximally
tolerated statin therapy to reduce the risk of major
adverse cardiovascular events in adults with
hypertriglyceridemia (≥150 mg/dL) who have either
established cardiovascular disease (CVD) or diabetes
and ≥2 additional risk factors for CVD. It is the only
omega-3 polyunsaturated fatty acid (PUFA) product
to be approved in the US for this indication. Icosapent
ethyl and two other omega-3 PUFA prescription
products (Lovaza, Epanova),...
Cenobamate (Xcopri) for Focal Seizures
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
as a
schedule V controlled substance.
DRUG INTERACTIONS — Taking cenobamate with
CNS depressants, including ...
The FDA has approved cenobamate (Xcopri – SK Life
Science) for oral treatment of partial-onset (focal)
seizures in adults.
Comparison Table: Some Nonopioid Analgesics for Pain (online only)
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
Drug Interactions
May decrease effectiveness of diuretics, beta
blockers, ACE inhibitors, and some ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Tezepelumab (Tezspire) for Severe Asthma
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
available in the US and the
first biologic drug to be approved for treatment
of severe asthma without ...
Tezepelumab-ekko (Tezspire – AstraZeneca/Amgen),
a subcutaneously administered thymic stromal
lymphopoietin (TSLP) blocker, has been approved
by the FDA for add-on maintenance treatment of
severe asthma in patients ≥12 years old. It is the first
TSLP blocker to become available in the US and the
first biologic drug to be approved for treatment
of severe asthma without phenotypic or biomarker
limitations.
Adagrasib (Krazati) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
. www.fdbhealth.com/drug-pricing-policy.
DRUG INTERACTIONS — Adagrasib is a CYP3A4
substrate and an inhibitor ...
Adagrasib (Krazati – Mirati Therapeutics), a RAS
GTPase family inhibitor, has received accelerated
approval from the FDA for oral treatment of KRAS
G12C-mutated locally advanced or metastatic non-small
cell lung cancer (NSCLC) in adults who received
at least one prior systemic therapy. Accelerated
approval was based on the objective response rate
and duration of response.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e17-8 doi:10.58347/tml.2023.1668f | Show Introduction Hide Introduction